Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Affiliation auteurs!!!! Error affiliation !!!!
TitreMolecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Type de publicationJournal Article
Year of Publication2015
AuteursGarg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, San Pedro JManuel Bra, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon M-L, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci J-E, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P
JournalFRONTIERS IN IMMUNOLOGY
Volume6
Pagination588
Date PublishedNOV 20
Type of ArticleArticle
ISSN1664-3224
Mots-clésanti-tumor immunity, immunogenicity, Immunotherapy, molecular dicine, oncoimmunology, patient prognosis, translational medicine
Résumé

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall mmunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called ``damage-associated molecular patterns'' (DAMPs). The emission of DAMPs and other mmunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.

DOI10.3389/fimmu.2015.00588